CliffBio
small molecule

VOQUEZNA DUAL PAK

AMOXICILLIN; VONOPRAZAN FUMARATE

Loss of exclusivityMay 2032FDA regulatory exclusivity expiry
CompanyPhathom Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameVOQUEZNA DUAL PAK
Active ingredientAMOXICILLIN; VONOPRAZAN FUMARATE
Strength500MG;EQ 20MG BASE
Dosage formCAPSULE, TABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2022
Marketing statusRX

Listed patents

PatentExpiresType
9186411August 2030product
7977488April 2030substance

Regulatory exclusivity

CodeExpires
GAINMay 2032
NCEMay 2027

More from Phathom Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.